1. Technical Field
The present disclosure relates to a system and related methods for employing electromagnetic energy in the microwave frequencies to produce a therapeutic effect on targeted tissue at a surgical site. In particular, the present disclosure relates to systems and methods of impedance matching to maximize energy delivered to target tissue.
2. Background of Related Art
Electromagnetic radiation may be used to heat cells to produce a therapeutic effect. For example, microwave energy has been used to selectively ablate certain types of cancerous cells found to denature at elevated temperatures slightly lower than temperatures normally injurious to healthy cells. Destroying cellular tissue in place may be less traumatic than removing it in a conventional surgery. Accordingly, a microwave ablation procedure may be an attractive option for many patients who are not good candidates for conventional surgery.
To denature many malignant growths of cells, temperatures above about 41.5° C. should be achieved. However, because thermal damage to most normal types of cells is commonly observed at temperatures above about 43° C., caution must be taken not to exceed this value. While it is true that electromagnetic energy used in ablative treatments is rapidly dissipated to non-destructive levels by natural processes such as conduction and convection due to circulating fluids, the temperature range suitable for ablative treatment is small, so great care must be taken in the application of microwave energy.
In a typical microwave ablation procedure, an antenna is positioned in the proximity of the tissue to be treated. For precise control, the antenna may be positioned directly inside the targeted tissue. A generator produces an electromagnetic oscillation, which may be transmitted over a coaxial transmission line to the antenna at its distal end. An electromagnetic field created by the antenna causes friction at a molecular level resulting in elevated temperatures in the vicinity thereof.
One concern in the management of microwave energy is impedance matching. In order to maximize the power transferred from a source to a load, the output impedance of the source should equal the input impedance of the load. Failure to match impedances may result in standing waves on the transmission line due to reflections of the incident power. In the case of microwave tissue ablation, the source is often configured with impedance throughout the appropriate frequency range approximately equal to that of the load to be ablated, which for most human tissue is approximately 50 ohms. However, as the target tissue is ablated, heating of the transmission line components and changes in the electrical properties of the target tissue tend to vary the load impedance over time. When the load impedances change, a greater portion of the power is reflected and the performance of the antenna system is diminished.
In light of the foregoing, a need exists for ablation systems and methods not only for preliminarily matching source impedances to load impedances, but also for accommodating changing tissue impedances occurring during the ablation procedure. In one embodiment, a microwave antenna is positioned in close proximity to a targeted tissue. Microwave energy is delivered to the antenna at a particular frequency through a transmission line, and a power signal reflected by the targeted tissue is measured. The particular frequency of the microwave energy is adjusted to reduce the energy reflected. A trocar may be used to position the antenna through the skin of a patient, and an initial frequency adjustment may be made to effect a source impedance to about 50 ohms. An output power may be adjusted in combination with the frequency adjustment. The reflected power signal measured may be compared to a predetermined threshold and frequency adjustments may made only when the reflected power signal exceeds the threshold value.
In another embodiment, a system for tissue ablation includes a microwave antenna configured for direct insertion into targeted tissue, a generator of microwave energy including a means for adjusting a frequency operatively connected to the antenna by a transmission line, a monitor operatively connected to the transmission line capable of sampling or measuring a reflected signal, and a means of communicating information concerning the reflected power to the generator. The monitor may include a dual directional coupler configured to sample at least one of the reflected signal and a forward signal. The means of communicating the reflected power information may include a visual display on an amplifier configured to amplify a signal output by a generator.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.
The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts throughout the several views.
The exemplary embodiments of the apparatus disclosed herein are discussed in terms of performing a diagnostic or therapeutic procedure involving collecting or delivering electrical signals relative to a subject. Such procedures are inclusive of, but, not limited to microwave tissue ablation and related treatments of diseases and body ailments of a subject. In the discussion that follows, the term “clinician” refers to a doctor, nurse, or other care provider and may include support personnel.
Referring initially to
As seen in
In accordance with the present disclosure, one method of matching the impedance of the antenna 110 to the source impedance is referred to as “active matching.” Such a method may require coupling additional electrical components to the microwave probe assembly 100 to electrically communicate with inner and outer conductors 120, 140. As seen in
Active matching control circuit 300 includes an input line 303 for receiving an output signal or energy from microwave generator 420 (
In operation, in order to match the impedance of the load on output line 305 to that of microwave probe 110, tuning diodes 310, 311 may be adjusted as needed or desired. PIN and/or varactor diodes 310, 311 may be used such that when a “DC” voltage is applied on supply lines 307, 309, the capacitance exhibited by diodes 310, 311 will vary in accordance with the applied voltage thereto. Inductors 314, 315 are selected to have high impedances over an appropriate range of frequencies so that inductors 314, 315 act as RF chokes, thereby keeping “DC” supply lines 307, 309 free from the alternating current supplied to output line 305. When diodes 310, 311 are appropriately tuned, capacitors 321, 322 and inductor 313 may compensate for a difference in impedance between the system and the tissue. Active matching control circuit 300 is placed as close as possible to the radiating portions 160a, 160b to minimize losses therebetween.
A simplified example of such tuning is described below with reference to
xL=j86.6Ω
xC=j116Ω
Now rotating the 200 ohm tissue impedance through the matching network, the tissue is in parallel with the 1.5 pf capacitor. First equivalent impedance ZL1 may be calculated using the parallel impedance formula.
Representing the tissue load and variable capacitor with the first equivalent impedance yields the circuit depicted in
ZL2=(50−j86.8)Ω+j86.6Ω≅50 Ω
Second equivalent impedance ZL2 may be calculated and represented in the circuit depicted in
In accordance with the present disclosure, a second method of matching the impedance of the microwave probe 110 to the source impedance is referred to as “frequency tuning.” As seen in
Microwave ablation system 400 includes a transmission line including a microwave frequency generator 420, an amplifier 430 electrically coupled to generator 420, a monitor such as coupler 440 electrically connected to amplifier 430, and a microwave energy delivery device or antenna 460 electrically coupled to 440 via a transmission cable 450. Microwave ablation system 400 further includes a measurement board 470 electrically coupled to coupler 440 and a microprocessor 480 in a communication line connecting the measurement board 470 with the frequency generator 420.
Frequency generator 420 may take any suitable form and should be configured to adjust the frequency of the output signal. The optimal frequencies for microwave tissue ablation are generally in the neighborhood of those frequencies best suited for heating water. By way of example, frequency generator 420 may be capable of producing output frequencies in the range of about 850 MHz to about 1.35 GHz, although higher frequencies are contemplated by the present disclosure. Amplifier 430 should be capable of amplifying the relatively low energy signal generated by frequency generator 420. Amplifier 430 should also be capable of communicating information about both the forward power and any reflected power signals present in system 400. Amplifier 430 may include a 300 Watt amplifier operating in the frequency range of 800 to 1000 MHz. Coupler 440 should be capable of sampling forward power from amplifier 430 and also the power reflected by the targeted tissue. Coupler 440 may include a 40 dB dual directional coupler having operating parameters suitable for use in this application. Measurement board 470 is in communication with coupler 450 and is capable of monitoring forward and reflected power signals and/or communicating impedance measurements.
Cable 450 and antenna 460 may take any suitable form for use in a frequency tuning application. Here it is contemplated that the coaxial cable 254 and microwave probe 110 discussed with reference to
Turning now to
The cable loss is partly a function of the characteristics of cable 450 (e.g., length diameter, materials of construction, etc.) and the frequency of the energy delivered therethrough. The cable loss may be readily calculated from such known characteristics. After a predetermined amount of time, an indication of the power reflected (i.e. not delivered to the target tissue) may be communicated through amplifier 430 to the operator by a display 435 on the amplifier 430 (Process 525). The correction factor determined for the cable loss may be applied to the value displayed for the reflected power at the amplifier 430 to determine the amount of energy reflected at the antenna 460.
A large reflected power, at antenna 460 in relation to the forward power at antenna 460, is representative of a substantial impedance mismatch. Conversely, smaller reflections are characteristic of having achieved a matched impedance between the target tissue and the load source or between the reflected power and the forward power. Some reflected power may be acceptable and thus not require any adjustments to the frequency output by generator 420 (Decision 535).
During operation, if some threshold value of reflected power is exceeded (Decision 535), the output frequency of generator 420 may be adjusted (upwardly or downwardly) to reduce the reflected power to a level below the threshold value (Process 540). This frequency adjustment may be accompanied by an adjustment to the output power of amplifier 430 if it is deemed necessary in order to deliver the necessary power to the target tissue (Process 545).
Even a single adjustment to the frequency of the output signal of generator 420 during the ablation procedure may have a substantial or significant effect on the effectiveness of the ablation procedure. In some embodiment, microwave ablation system 400 may include, for example, a microcontroller 480 capable of automatically making many frequency adjustments during a given period of time. The ablation cycle may continue, continuously monitoring the reflected power and making frequency adjustments as necessary, until the target tissue has been sufficiently ablated (Decision 530). When the tissue has been sufficiently ablated, energy delivery to the tissue may cease (Process 550).
An ablation procedure performed on cow liver tissue yielded the exemplary values presented in Table 1 below. Initially the output frequency of generator 420 was set at 925 MHz, and the amplifier 430 was set to output 31 Watts. The output power from the amplifier was transmitted through a cable 450 known to have a loss of 1.25 dB. A cable loss (dB) is related to a correction factor (P) by the equation dB=10(log P). A correction factor of about 1.33 was thus determined for the cable 450. Dividing the 31 Watt output power of the amplifier 430 by the 1.33 correction factor yielded the initial value recorded for the load power. This initial value of 23.25 Watts represents the power delivered to the cow liver tissue load or the output power of the amplifier 430 less the power lost in the cable 450.
After the initial value of load power was thus calculated, subsequent values recorded for load power were based on a value recorded for the power reflected by the tissue. The values for power reflected were observed on the display 435 of amplifier 430 and thus represent the power reflected by the tissue load not lost in the cable 450 as the signal returned from the tissue to the amplifier 430. To determine the amount of power actually reflected by the tissue, the 1.33 correction factor was multiplied by the power reflected and recorded as the corrected power reflected. The values listed for load power subsequent to the initial value were calculated by subtracting the corrected power reflected from the initial load power calculated. The values for load power then represent the power delivered to the tissue and not reflected by the tissue. Initially the power reflected was recorded as Low because the power reflected was below the range detectable by the amplifier 430. Whenever possible, an impedance reading was recorded as illustrated in Table 1 below. Impedance readings may be used to determine a frequency needed for tuning.
As can be seen in Table 1, the power reflected by the tissue generally increased over time as the tissue was heated, just as expected. The output frequency of generator 420 was adjusted to 930 MHz after 1.5 minutes, to 935 MHz after 2 minutes, and 940 MHz after 2.5 minutes of the ablation procedure. These adjustments yielded a reflected power of 4 Watts after 10 minutes. With no frequency adjustments, a max reflected power of about 8 Watts could be expected around 10 minutes. Thus, a comparison of these reflected power values demonstrates the effect of frequency adjustments on the delivery of energy to the tissue.
Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.
This application is a continuation of U.S. application Ser. No. 11/900,874, filed on Sep. 13, 2007, now U.S. Pat. No. 8,747,398, the entire contents of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1995526 | Wappler | Mar 1935 | A |
4204549 | Paglione | May 1980 | A |
4228809 | Paglione | Oct 1980 | A |
4311154 | Sterzer et al. | Jan 1982 | A |
4375220 | Matvias | Mar 1983 | A |
4494539 | Zenitani et al. | Jan 1985 | A |
4534347 | Taylor | Aug 1985 | A |
4580557 | Hertzmann | Apr 1986 | A |
4612940 | Kasevich et al. | Sep 1986 | A |
4632127 | Sterzer | Dec 1986 | A |
4632128 | Paglione et al. | Dec 1986 | A |
4638436 | Badger et al. | Jan 1987 | A |
4657015 | Irnich | Apr 1987 | A |
4672980 | Turner | Jun 1987 | A |
4741348 | Kikuchi et al. | May 1988 | A |
4744372 | Kikuchi et al. | May 1988 | A |
4747416 | Kikuchi et al. | May 1988 | A |
4753248 | Engler et al. | Jun 1988 | A |
4799034 | Silverman et al. | Jan 1989 | A |
4815479 | Carr | Mar 1989 | A |
4860752 | Turner | Aug 1989 | A |
4860770 | Kikuchi et al. | Aug 1989 | A |
4873995 | Kikuchi et al. | Oct 1989 | A |
4884580 | Kikuchi et al. | Dec 1989 | A |
4945912 | Langberg | Aug 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4967765 | Turner et al. | Nov 1990 | A |
5019076 | Yamanashi et al. | May 1991 | A |
5025810 | Kikuchi et al. | Jun 1991 | A |
5033478 | Kikuchi et al. | Jul 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5148814 | Kikuchi et al. | Sep 1992 | A |
5188122 | Phipps et al. | Feb 1993 | A |
5211570 | Bitney | May 1993 | A |
5220927 | Astrahan et al. | Jun 1993 | A |
5234004 | Hascoet et al. | Aug 1993 | A |
5249585 | Turner et al. | Oct 1993 | A |
5275597 | Higgins et al. | Jan 1994 | A |
5295955 | Rosen et al. | Mar 1994 | A |
5330518 | Neilson et al. | Jul 1994 | A |
5342349 | Kaufman | Aug 1994 | A |
5344435 | Turner et al. | Sep 1994 | A |
5354325 | Chive et al. | Oct 1994 | A |
5364392 | Warner et al. | Nov 1994 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5405346 | Grundy et al. | Apr 1995 | A |
5433740 | Yamaguchi | Jul 1995 | A |
5571098 | Domankevitz et al. | Nov 1996 | A |
5571154 | Ren | Nov 1996 | A |
5584830 | Ladd et al. | Dec 1996 | A |
5620480 | Rudie | Apr 1997 | A |
5628771 | Mizukawa et al. | May 1997 | A |
5693082 | Warner et al. | Dec 1997 | A |
5800494 | Campbell et al. | Sep 1998 | A |
5836943 | Miller, III | Nov 1998 | A |
5904709 | Arndt et al. | May 1999 | A |
5922013 | Fallik | Jul 1999 | A |
5938692 | Rudie | Aug 1999 | A |
5944022 | Nardella et al. | Aug 1999 | A |
5957969 | Warner et al. | Sep 1999 | A |
5961871 | Bible et al. | Oct 1999 | A |
5967976 | Larsen et al. | Oct 1999 | A |
6016452 | Kasevich | Jan 2000 | A |
6019757 | Scheldrup | Feb 2000 | A |
6022346 | Panescu et al. | Feb 2000 | A |
6032078 | Rudie | Feb 2000 | A |
6047216 | Carl et al. | Apr 2000 | A |
6067475 | Graves et al. | May 2000 | A |
6068627 | Orszulak et al. | May 2000 | A |
6093028 | Yang | Jul 2000 | A |
6097985 | Kasevich et al. | Aug 2000 | A |
6106520 | Laufer et al. | Aug 2000 | A |
6122551 | Rudie et al. | Sep 2000 | A |
6134476 | Arndt et al. | Oct 2000 | A |
6136020 | Faour | Oct 2000 | A |
6161048 | Sluijter et al. | Dec 2000 | A |
6163726 | Wolf | Dec 2000 | A |
6167313 | Gray et al. | Dec 2000 | A |
6175768 | Arndt et al. | Jan 2001 | B1 |
6179832 | Jones et al. | Jan 2001 | B1 |
6181970 | Kasevich | Jan 2001 | B1 |
6188930 | Carson | Feb 2001 | B1 |
6216703 | Manker et al. | Apr 2001 | B1 |
6226553 | Carl et al. | May 2001 | B1 |
6228079 | Koenig | May 2001 | B1 |
6233490 | Kasevich | May 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6251128 | Knopp et al. | Jun 2001 | B1 |
6272384 | Simon et al. | Aug 2001 | B1 |
6273886 | Edwards et al. | Aug 2001 | B1 |
6275738 | Kasevich et al. | Aug 2001 | B1 |
6289249 | Arndt et al. | Sep 2001 | B1 |
6293941 | Strul et al. | Sep 2001 | B1 |
6312391 | Ramadhyani et al. | Nov 2001 | B1 |
6325799 | Goble | Dec 2001 | B1 |
6334074 | Spertell | Dec 2001 | B1 |
6347251 | Deng | Feb 2002 | B1 |
6366818 | Bolmsjo | Apr 2002 | B1 |
6380815 | Fehrenbach et al. | Apr 2002 | B1 |
6383183 | Sekino et al. | May 2002 | B1 |
6402742 | Blewett et al. | Jun 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6451015 | Rittman, III et al. | Sep 2002 | B1 |
6470217 | Fenn et al. | Oct 2002 | B1 |
6477426 | Fenn et al. | Nov 2002 | B1 |
6485486 | Trembly et al. | Nov 2002 | B1 |
6490488 | Rudie et al. | Dec 2002 | B1 |
6494880 | Swanson et al. | Dec 2002 | B1 |
6496736 | Carl et al. | Dec 2002 | B1 |
6496738 | Carr | Dec 2002 | B2 |
6503191 | Miller | Jan 2003 | B1 |
6512956 | Arndt et al. | Jan 2003 | B2 |
6522931 | Manker et al. | Feb 2003 | B2 |
6526320 | Mitchell | Feb 2003 | B2 |
6542767 | McNichols et al. | Apr 2003 | B1 |
6544069 | Enriquez, Sr. et al. | Apr 2003 | B1 |
6582425 | Simpson | Jun 2003 | B2 |
6582427 | Goble et al. | Jun 2003 | B1 |
6592579 | Arndt et al. | Jul 2003 | B2 |
6628990 | Habib et al. | Sep 2003 | B1 |
6640139 | Ueberle | Oct 2003 | B1 |
6666862 | Jain et al. | Dec 2003 | B2 |
6671535 | McNichols et al. | Dec 2003 | B1 |
6675050 | Arndt et al. | Jan 2004 | B2 |
6685701 | Orszulak et al. | Feb 2004 | B2 |
6689131 | McClurken | Feb 2004 | B2 |
6690976 | Fenn et al. | Feb 2004 | B2 |
6723091 | Goble et al. | Apr 2004 | B2 |
6725095 | Fenn et al. | Apr 2004 | B2 |
6743225 | Sanchez et al. | Jun 2004 | B2 |
6752804 | Simpson et al. | Jun 2004 | B2 |
6771139 | Schultheiss et al. | Aug 2004 | B2 |
6788977 | Fenn et al. | Sep 2004 | B2 |
6790206 | Panescu | Sep 2004 | B2 |
6796980 | Hall | Sep 2004 | B2 |
6823218 | Berube | Nov 2004 | B2 |
6847848 | Sterzer et al. | Jan 2005 | B2 |
6866624 | Chornenky et al. | Mar 2005 | B2 |
6939348 | Malecki et al. | Sep 2005 | B2 |
6944504 | Arndt et al. | Sep 2005 | B1 |
6955675 | Jain | Oct 2005 | B2 |
6957108 | Turner et al. | Oct 2005 | B2 |
6962586 | Berube et al. | Nov 2005 | B2 |
6974463 | Magers et al. | Dec 2005 | B2 |
6986764 | Davenport et al. | Jan 2006 | B2 |
6986770 | Hood | Jan 2006 | B2 |
6994704 | Qin et al. | Feb 2006 | B2 |
7041096 | Malis et al. | May 2006 | B2 |
7066933 | Hagg | Jun 2006 | B2 |
7070595 | Ormsby et al. | Jul 2006 | B2 |
7089064 | Manker et al. | Aug 2006 | B2 |
7093601 | Manker et al. | Aug 2006 | B2 |
7105011 | Auge, II | Sep 2006 | B2 |
7113832 | Longo | Sep 2006 | B2 |
7115121 | Novak | Oct 2006 | B2 |
7115126 | Berube et al. | Oct 2006 | B2 |
7122031 | Edwards et al. | Oct 2006 | B2 |
7131445 | Amoah | Nov 2006 | B2 |
7169144 | Hoey et al. | Jan 2007 | B2 |
7194297 | Talpade et al. | Mar 2007 | B2 |
7195627 | Amoah et al. | Mar 2007 | B2 |
7197363 | Prakash et al. | Mar 2007 | B2 |
7200445 | Dalbec et al. | Apr 2007 | B1 |
7202747 | Forse et al. | Apr 2007 | B2 |
7203556 | Daners | Apr 2007 | B2 |
7211081 | Goble | May 2007 | B2 |
7214224 | Goble | May 2007 | B2 |
7220260 | Fleming et al. | May 2007 | B2 |
7226447 | Uchida et al. | Jun 2007 | B2 |
7594913 | Ormsby et al. | Sep 2009 | B2 |
8747398 | Behnke | Jun 2014 | B2 |
20010008966 | Arndt et al. | Jul 2001 | A1 |
20010016762 | Carr | Aug 2001 | A1 |
20010020178 | Arndt et al. | Sep 2001 | A1 |
20020000234 | Manker et al. | Jan 2002 | A1 |
20020165529 | Danek | Nov 2002 | A1 |
20020193849 | Fenn et al. | Dec 2002 | A1 |
20030014043 | Henry et al. | Jan 2003 | A1 |
20030023238 | Manker et al. | Jan 2003 | A1 |
20030055471 | Fenn et al. | Mar 2003 | A1 |
20030065317 | Rudie et al. | Apr 2003 | A1 |
20030069619 | Fenn et al. | Apr 2003 | A1 |
20030144655 | Panescu | Jul 2003 | A1 |
20030191513 | Manker et al. | Oct 2003 | A1 |
20030199863 | Swanson et al. | Oct 2003 | A1 |
20040032301 | Schultheiss et al. | Feb 2004 | A1 |
20040049254 | Longo | Mar 2004 | A1 |
20040122420 | Amoah | Jun 2004 | A1 |
20040133254 | Sterzer et al. | Jul 2004 | A1 |
20040193147 | Malecki et al. | Sep 2004 | A1 |
20040215179 | Swoyer et al. | Oct 2004 | A1 |
20040215182 | Lee | Oct 2004 | A1 |
20040243120 | Orszulak et al. | Dec 2004 | A1 |
20040243200 | Turner et al. | Dec 2004 | A1 |
20050038419 | Arnold et al. | Feb 2005 | A9 |
20050137662 | Morris et al. | Jun 2005 | A1 |
20050143795 | Habib et al. | Jun 2005 | A1 |
20050149010 | Turovskiy et al. | Jul 2005 | A1 |
20050149012 | Penny et al. | Jul 2005 | A1 |
20050182393 | Abboud et al. | Aug 2005 | A1 |
20050184922 | Ida et al. | Aug 2005 | A1 |
20050228370 | Sterzer et al. | Oct 2005 | A1 |
20050240239 | Boveja et al. | Oct 2005 | A1 |
20050245920 | Vitullo et al. | Nov 2005 | A1 |
20060004351 | Arless et al. | Jan 2006 | A1 |
20060015161 | Longo et al. | Jan 2006 | A1 |
20060015162 | Edward et al. | Jan 2006 | A1 |
20060030914 | Eggers et al. | Feb 2006 | A1 |
20060106375 | Werneth et al. | May 2006 | A1 |
20060116673 | Gauthier et al. | Jun 2006 | A1 |
20060142753 | Francischelli et al. | Jun 2006 | A1 |
20060287649 | Ormsby et al. | Dec 2006 | A1 |
Number | Date | Country |
---|---|---|
9735639 | Oct 1997 | WO |
Entry |
---|
European Search Report, Application No. EP 2 036 512 A1 dated Nov. 27, 2008. |
European Search Report for European Patent Appln. No. 08015842.1 dated Jan. Oct. 1, 2010. |
Number | Date | Country | |
---|---|---|---|
20140296840 A1 | Oct 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11900874 | Sep 2007 | US |
Child | 14300824 | US |